Pathophysiology of multiple myeloma bone disease
- PMID: 17996587
- DOI: 10.1016/j.hoc.2007.08.009
Pathophysiology of multiple myeloma bone disease
Abstract
Multiple myeloma is a plasma cell malignancy characterized by the frequent development of osteolytic bone lesions. The multiple myeloma-induced bone destruction is a result of the increased activity of osteoclasts that occurs adjacent to multiple myeloma cells. This activity is accompanied by suppressed osteoblast differentiation and activity, resulting in severely impaired bone formation and development of devastating osteolytic lesions. Recently the biologic mechanism involved in the imbalance between osteoclast activation and osteoblast inhibition induced by multiple myeloma cells has begun to be clarified. In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed.
Similar articles
-
Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.Br J Haematol. 2010 Feb;148(4):551-61. doi: 10.1111/j.1365-2141.2009.07980.x. Epub 2009 Nov 16. Br J Haematol. 2010. PMID: 19919653
-
Update on the pathogenesis of osteolysis in multiple myeloma patients.Acta Biomed. 2004 Dec;75(3):143-52. Acta Biomed. 2004. PMID: 15796087 Review.
-
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.Dan Med Bull. 2011 May;58(5):B4277. Dan Med Bull. 2011. PMID: 21535989 Review.
-
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104. J Bone Miner Res. 2009. PMID: 19016584
-
Pathogenesis of myeloma bone disease.J Cell Biochem. 2010 Feb 1;109(2):283-91. doi: 10.1002/jcb.22403. J Cell Biochem. 2010. PMID: 20014067
Cited by
-
Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.Sci Rep. 2022 Jan 7;12(1):30. doi: 10.1038/s41598-021-03748-0. Sci Rep. 2022. PMID: 34996933 Free PMC article.
-
Bone building with bortezomib.J Clin Invest. 2008 Feb;118(2):462-4. doi: 10.1172/JCI34734. J Clin Invest. 2008. PMID: 18219395 Free PMC article.
-
Enhancing prognosis in multiple myeloma bone disease: insights from a retrospective analysis of surgical interventions.Front Surg. 2024 Dec 19;11:1433265. doi: 10.3389/fsurg.2024.1433265. eCollection 2024. Front Surg. 2024. PMID: 39749125 Free PMC article.
-
Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.Blood. 2009 Oct 15;114(16):3413-21. doi: 10.1182/blood-2009-03-211920. Epub 2009 Aug 6. Blood. 2009. PMID: 19661269 Free PMC article.
-
Multiple Myeloma (Part 2) - Update on The Approach to Bone Disease.Rev Bras Ortop (Sao Paulo). 2023 Jun 29;58(3):368-377. doi: 10.1055/s-0043-1770150. eCollection 2023 Jun. Rev Bras Ortop (Sao Paulo). 2023. PMID: 37396088 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical